Results 31 to 40 of about 8,290,554 (306)

Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis

Therapeutic Advances in Gastroenterology, 2016
As biologic-based medication options for ulcerative colitis expand, our understanding of their optimal use in clinical practice is advancing as well.
M. Anthony Sofia, David T. Rubin
doaj   +1 more source

Mucus Plug Score predicts clinical and pulmonary function response to biologic therapy in patients with severe Asthma.

Journal of Allergy and Clinical Immunology: In Practice
BACKGROUND Mucus plugging has been identified as an important feature of severe asthma contributing to airway obstruction and disease severity. Recently, improvement of mucus plugging has been found upon treatment with several biologic therapies ...
J. Götschke, Julia Walter, G. Leuschner, M. Gerckens, Melanie Götschke, P. Mertsch, C. Mümmler, A. Lenoir, M. Barnikel, Julien Dinkel, J. Behr, N. Kneidinger, Judith Spiro, K. Milger   +13 more
semanticscholar   +1 more source

New onset or worsening of psoriasis following biologic therapy: A case series

International Journal of Immunopathology and Pharmacology, 2017
Biologic therapies may cause so-called “paradoxical side-effects,” that is, the onset or exacerbation of new symptoms/diseases for which biological treatment should be effective. Among these, psoriatic skin lesions have been described.
Vincenzo Bruzzese, Vincenzo De Francesco, Cesare Hassan, Roberto Lorenzetti, Palma Scolieri, Cinzia Marrese, Angelo Zullo   +6 more
doaj   +1 more source

Biologic Therapies for Psoriasis

The Journal of Rheumatology Supplement, 2009
Psoriasis is a common chronic inflammatory skin disease that may lead to disability and significant effects on patients' quality of life. A challenge in psoriasis management is to use an effective therapy early in the disease course in order to achieve a safe and well tolerated maintenance of remission with an improvement of both skin and joint ...
de FELICE, C., ARDIGO, M., BERARDESCA, E.   +2 more
openaire   +3 more sources

Biologic Therapy and Cardiometabolic Risk in Psoriasis: A Retrospective Review

Dermatologic Therapy
Psoriasis is a systemic inflammatory disease with increased cardiometabolic risk including dyslipidaemia and diabetes. Biologic therapy effectively treats the cutaneous inflammatory burden of psoriasis and evolving evidence suggests potential to reduce ...
Annika Smith, Aidin Karahasan, D. Yi, Sanjay Yapabandara, James Elhindi, P. Fernández-Peñas, Clara Chow, Sarah Zaman   +7 more
semanticscholar   +1 more source

Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core

Circulation Cardiovascular Imaging, 2020
Supplemental Digital Content is available in the text. Background: Lipid-rich necrotic core (LRNC), a high-risk coronary plaque feature assessed by coronary computed tomography angiography, is associated with increased risk of future cardiovascular ...
Harry Choi, Domingo E. Uceda, A. Dey, K. Abdelrahman, Milena Aksentijevich, J. Rodante, Youssef Elnabawi, A. Reddy, A. Keel, Julie A Erb-Alvarez, H. Teague, M. Playford, Wunan Zhou, Marcus Y. Chen, J. Gelfand, D. Bluemke, A. Buckler, N. Mehta   +17 more
semanticscholar   +1 more source

Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development

Antibodies
Many patients with inflammatory bowel disease (IBD) experience a loss of effectiveness to biologic therapy (i.e., anti-TNF therapy, etc.). Therefore, in addition to the adverse effects of the treatment, these patients also face failure to achieve and ...
T. Velikova, Metodija Sekulovski, Monika Peshevska-Sekulovska   +2 more
semanticscholar   +1 more source

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics

Dermatology and Therapy, 2020
While biologic therapies for psoriasis are effective for many patients, some patients may lose response, have inadequate control of disease, or develop intolerance to certain biologic agents.
Alan Menter, April Armstrong, Abby Van Voorhees, Clive Liu, Abby Jacobson   +4 more
doaj   +1 more source

Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy

Respiratory Medicine, 2020
Background It is unclear whether asthma and asthma medications increase or decrease the risk of severe COVID-19, and this is particularly true for patients with severe asthma receiving biologics.
K. Eger, S. Hashimoto, G. Braunstahl, A. ten Brinke, K. Patberg, Annelies Beukert, F. Smeenk, der Brugge Simone van der Sar-van, E. J. Weersink, E. Bel   +9 more
semanticscholar   +1 more source

Real world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland

Scientific Reports
Advances in biologic and targeted synthetic DMARDs have expanded treatment options for spondylarthritis. Despite improvements with TNF inhibitors, many patients remain refractory.
Anna Felis-Giemza, Małgorzata Stasiek, Karolina Palej, Marta Wysmołek-Sołtysik, Marta Łosoś, Sandra Stańczyk, Joanna Werońska-Tatara, Jakub Wroński   +7 more
doaj   +1 more source